## Abstract ## BACKGROUND Mutations in fibroblast growth factor 3 receptor (__FGFR3__) are frequent events in low‐grade bladder tumors. To assess the potential utility of the detection of __FGFR3__ mutations in a screening modality, the authors analyzed urine sediment DNA samples from 192 patients
Preliminary identification of a tumor-associated glycoprotein in bilharzial bladder cancer urine
✍ Scribed by Gene I. Higashi; Adel M. A. El-Asfahani
- Publisher
- John Wiley and Sons
- Year
- 1983
- Tongue
- French
- Weight
- 469 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
A tumor‐associated antigen was preliminarily identified in urine from bilharzial (squamous‐cell carcinoma) bladder cancer patients. Monospecific rabbit antisera were made by immunization with concentrated bladder cancer urine and exhaustive absorption with insoluble normal human serum and urine. The urine tumor‐associated antigen was identical to an antigen from 3M KCl bladder tumor extract by immunodiffusion. The antigen in urine was found in nine of 10 bladder cancer patients and was absent from normal urine and serum by immunodiffusion and immunoelectrophoresis. The antigen was a concanavalin‐A‐binding glycoprotein which was anodal on immunoelectrophoresis. It was stable up to 2 years at‐20°C and did not cross‐react with carcinoembryonik antigen or with Schistosoma haematobium antigens.
📜 SIMILAR VOLUMES
High frequency loss of 3p21.3 region where RASSF1A located was demonstrated in several tumors. We aimed to investigate the methylation status of RASSF1A and the frequency of LOH in 3p21.3 region in bladder cancer. Three bladder cancer cell lines, 40 cases of bladder TCC and 14 cases of paired voided
## Abstract The original article to which this Erratum refers was published in Cancer (2003) 98(4) 737–44